Hajdu-Cheney Syndrome Linked to Acroosteolysis in Rare Case Report

A rare genetic disorder known as Hajdu-Cheney Syndrome (HCS) has been identified as a potential cause of acroosteolysis, a condition characterized by the progressive resorption of the distal phalanges, according to a case report published in Cureus. The findings highlight the importance of recognizing HCS in differential diagnoses for patients presenting with unexplained bone loss in the hands and feet.

What Is Hajdu-Cheney Syndrome?

Hajdu-Cheney Syndrome is a congenital disorder caused by mutations in the NOTCH2 gene, which plays a critical role in skeletal development. It occurs in approximately 1 in 200,000 live births, according to the National Organization for Rare Disorders (NORD). Key features include craniofacial abnormalities, joint hypermobility, and osteoporosis, often leading to frequent fractures and short stature.

How Does HCS Relate to Acroosteolysis?

Acroosteolysis, the resorption of the terminal phalanges, is a hallmark of HCS. A 2023 case report details a 34-year-old woman with HCS who presented with progressive digital shortening and joint instability. Imaging confirmed acroosteolysis, with radiographs showing loss of the distal phalanges in all fingers and toes. Researchers noted that this connection between HCS and acroosteolysis is underreported in the literature, despite being a defining feature of the syndrome.

Diagnosis and Management

Diagnosis of HCS typically involves genetic testing for NOTCH2 mutations and radiographic evaluation. Management focuses on symptomatic relief, including bisphosphonates to slow bone loss and physical therapy to maintain joint function. The case report emphasizes the need for multidisciplinary care, involving orthopedic surgeons, geneticists, and rheumatologists.

Why This Matters for Clinicians

Early recognition of HCS is critical to prevent complications like pathologic fractures and severe deformities. A 2022 review in Orphanet Journal of Rare Diseases highlighted that acroosteolysis often precedes other HCS symptoms, making it a potential early indicator. However, the condition remains underdiagnosed due to its rarity and overlapping features with other osteodysplasias.

Future Research Directions

Experts call for larger studies to better understand the molecular mechanisms linking NOTCH2 mutations to acroosteolysis. A 2023 study in Genetics in Medicine suggested that targeting the NOTCH signaling pathway could offer therapeutic avenues. Until then, clinicians are advised to consider HCS in patients with unexplained acroosteolysis, particularly when accompanied by other skeletal anomalies.